Colorectal Adenocarcinoma
Conditions
Brief summary
Electrochemotherapy (ECT) is a non-thermal tumour ablation modality. It consists of the local potentiation, by means of local reversible electroporation of tumour tissues, of the antitumor activity of non-permeant or poorly permeant anticancer drugs already possessing intrinsic cytotoxicity. ECT has proved to be effective in the treatment of various cutaneous tumour nodules of any origin. Mostly ECT is offered to patients in case of multiple cutaneous metastases, when they cannot be excised, due to their number or localization. This study investigate the application of ECT in the treatment of liver metastases from colorectal adenocarcinoma, for which other thermal cytoreductive methods would be risky compared to the supposed expected clinical benefits.
Interventions
Sponsors
IGEA
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female patients \> 18 years of age * Histological confirmed colorectal adenocarcinoma * Histological or clinically confirmed metastatic colorectal adenocarcinoma lesions (liver lesions only are considered as metastatic disease) and not resecable. * A single liver lesion may not exceed 3 cm * Liver lesions must not have a depth greater than 2 cm from hepatic surface (Glisson Capsule) (measured clinically if possible otherwise on the basis of CT/ultrasound examination) * A life expectancy of at least 6 months. * Patients with a ECOG performance status \< 2 * Signed Informed Consent * Patient must be mentally capable of understanding the information given. * Patient must give informed consent.
Exclusion criteria
* Age less than 18 years. * Patient pregnant or lactating (no contraceptive method is contraindicated, a pregnancy test will be administered to all women of childbearing age) * Life-threatening infection and/or heart failure and/or liver failure and/or other severe systemic pathologies that preclude laparotomy * Strumental analysis confirmed ascites. * Impaired kidney function. * Significant reduction in respiratory function. * Allergic reaction to bleomycin. * Coagulation disturbances * Patients with
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastasesSafety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events | 24 hours from Electrochemotherapy treatment | Safety and feasibility evaluation of Electrochemotherapy treatment of liver metastases as meaured by unexpected intraoperative adverse events and related postoperative complications. |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival | 6 months from Electrochemotherapy treatment |
| Disease free survival | 6 months from Electrochemotherapy treatment |
| Quality of Life (Karnofsky performance status) | 30 days and 6 months from ECT treatment |
| Objective response evaluation of treated liver metastases following RECIST criteria | 30 days and 6 months from Electrochemotherapy treatment |
| Toxicity of Electrochemotherapy treatment of liver metastases as meaured by unexpected postoperative complications related to treatment | 7 days |
Outcome results
None listed